Core Viewpoint - Country Garden Holdings has been officially included in the FTSE Russell Global Equity Index Series, marking its second inclusion in a major global index within a month, following its addition to the MSCI index [1][2]. Group 1: Index Inclusion Impact - The inclusion in the FTSE Russell and MSCI indices is expected to lead to significant passive capital inflows, as funds tracking these indices will need to purchase Country Garden shares according to their weightings [1]. - The recent rebalancing is projected to trigger over $15 billion in net passive capital inflows into the Chinese market, making it the largest beneficiary in the Asia-Pacific region [1]. Group 2: Market Liquidity and Credibility - The overall liquidity of the Chinese stock market is anticipated to improve due to the large-scale passive capital inflows, which will also enhance the liquidity of newly included stocks like Country Garden [2]. - Inclusion in the FTSE and MSCI indices serves as a "passport" to the global capital market, reflecting an official endorsement of Country Garden's improving fundamentals and risk mitigation progress [2].

Core Viewpoint - Country Garden has been included in the FTSE Russell Global Stock Index series, effective March 20, marking it as the only newly added real estate stock in this adjustment [1][2]. Group 1: Index Inclusion Impact - Country Garden has been added to two major global indices within a month, first to the MSCI index on February 27, where it was the only new real estate stock among 21 additions and 11 removals [1][2]. - The inclusion in these indices is expected to lead to a significant influx of passive capital, as global passive funds tracking these indices will be required to purchase Country Garden shares according to their weightings, creating a stable incremental buying pressure [1][2].

Financial Data and Key Metrics Changes - Adjusted EBITDA for 2025 was $395 million, exceeding guidance and reflecting strong operating results [4][16] - Q4 Adjusted EBITDA was $72.7 million, surpassing expectations, with revenue of $2.4 billion, a 9.2% increase year-over-year [13][14] - Full-year revenue increased by 8.2% to $9.2 billion, while net income for the year decreased to $82 million from $143 million due to non-operational items [14][16] Business Line Data and Key Metrics Changes - Fresh Fruit segment delivered EBITDA of $189 million for 2025, impacted by elevated sourcing costs but supported by strong banana demand [9][17] - Diversified EMEA segment achieved an Adjusted EBITDA of $150 million, a 14% increase year-on-year, driven by strong performance in Spain and the Nordics [10][11] - Diversified Americas segment saw a 21% increase in full-year Adjusted EBITDA, driven by strong revenue growth in North America [11][18] Market Data and Key Metrics Changes - The banana market remains robust in North America and Europe, with strong demand supporting pricing despite sourcing challenges [9][10] - The EMEA segment benefited from favorable foreign exchange impacts and strong underlying performance in key markets [17] - The Americas segment experienced excellent product-led growth, particularly in kiwis and citrus [11][18] Company Strategy and Development Direction - The company successfully exited the Fresh Vegetables business, allowing for a more focused capital allocation strategy [5][6] - A $100 million share repurchase program was approved to enhance capital allocation flexibility [6][22] - The company aims to target Adjusted EBITDA of at least $400 million for 2026, focusing on cost control and operational efficiencies [24][25] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by elevated sourcing costs and weather-related disruptions but expressed optimism for recovery in 2026 [9][29] - The company is focused on maintaining operational momentum and leveraging strategic investments to drive growth [23][24] - Management highlighted the importance of navigating macroeconomic uncertainties while targeting growth in core business areas [25][60] Other Important Information - The company completed a $1.2 billion renewal of credit facilities, enhancing financial capacity for future growth initiatives [5] - Cash capital expenditure for 2025 was $121.5 million, with a forecast of approximately $100 million for 2026 [21][20] - The company transitioned to full U.S. domestic issuer filings, which is expected to improve eligibility for inclusion in broader U.S. equity indices [6][52] Q&A Session Summary Question: Could you elaborate on the major factors in your 2026 outlook? - Management noted that while demand trends are robust, fruit sourcing costs remain a challenge, and they are engaging in constructive dialogue with customers regarding pricing [27][29] Question: What is the expected cash flow conversion relative to the $400 million EBITDA target? - Management indicated a target for free cash flow conversion of 30% to 35% over the longer term, with expectations for more normalized levels in 2026 [33][35] Question: Can you discuss the impact of the Ecuador port asset sales on cost structure and capital allocation? - Management stated that the sale would be neutral from a cost perspective and emphasized a dynamic capital allocation process focusing on growth opportunities [43][44] Question: What are the key milestones for index inclusion? - Management expressed optimism about seeking inclusion in smaller S&P indices and MSCI indices, with a focus on the S&P 600 [51][53]

Group 1 - The company, Jinfang Pharmaceutical-B (02595), has been included in multiple indices, including the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Index, and Hang Seng Innovative Drug Index, effective March 9, 2026 [1] - The company will also be added to the MSCI Global Small Cap Index, with the adjustment effective after the market close on February 27, 2026 [1] - Inclusion in these indices will allow the company's stock to be traded through the Hong Kong Stock Connect and Shenzhen Stock Connect, enhancing its accessibility to investors [1] Group 2 - The company is also selected for several other Hang Seng indices, such as the Hang Seng Composite Small Cap Index and the Hang Seng Healthcare Index, reflecting investor recognition of its value and growth potential [2] - The board anticipates that this inclusion will improve stock liquidity, broaden the shareholder base, and diversify the types of shareholders, contributing to the company's long-term stable development [2] - The company aims to strengthen its leading position in the RAS sector and enhance its international competitiveness in innovative drug fields, driving value creation through its R&D advantages [2]

Group 1 - SpaceX is seeking to accelerate its stock price increase following its planned IPO later this year by negotiating with major index providers like Nasdaq for faster inclusion into key indices [1][2] - Typically, companies must wait several months to a year after going public to qualify for inclusion in major indices like the S&P 500 or Nasdaq 100, which helps attract investment from both retail and institutional investors [1] - As part of its IPO strategy, SpaceX aims to bypass traditional rules to provide liquidity to shareholders sooner, with advisors proposing modifications to index inclusion policies that could also benefit other high-valuation private companies [1] Group 2 - SpaceX's previous valuation was $800 billion before acquiring xAI, with a target of exceeding $1 trillion at the time of its IPO, potentially making it the largest IPO in U.S. history [2] - Other AI startups like OpenAI and Anthropic are also expected to go public this year, marking a significant period for the IPO market [2] - Establishing a stable investor base is crucial for the long-term success of these upcoming public companies [2]

Core Viewpoint - SpaceX is preparing for an IPO and aims to expedite its inclusion in major stock indices to enhance liquidity for its shareholders [1] Group 1: IPO Strategy - SpaceX has recently merged with xAI and is in discussions with major index providers, including Nasdaq, to facilitate quicker inclusion in key indices [1] - Typically, companies must wait months or even a year after going public to be added to indices like the S&P 500 or Nasdaq 100, but SpaceX seeks to bypass this traditional waiting period [1] Group 2: Market Impact - Inclusion in major indices would open up access to retail and institutional funds, particularly from index-tracking funds that must hold constituent stocks [1] - SpaceX's latest valuation stands at $800 billion, with a target valuation exceeding $1 trillion, which would make it the largest IPO in U.S. history if successful [1]

Core Viewpoint - 易鑫集团's stock price increased by over 7% towards the end of trading, reflecting positive market sentiment following the announcement of a renewed strategic cooperation agreement with 精真估 for used car services [1] Group 1: Strategic Developments - 易鑫集团 announced a three-year renewal of its strategic cooperation agreement with 精真估, which will continue to provide used car valuation and related services [1] - The annual service fee cap under the existing agreement was raised from 50 million to 60 million yuan, indicating the company's confidence in the growing demand for used car services [1] Group 2: Market Position and Performance - 易鑫集团 is a subsidiary of Tencent, and the deepening collaboration with Tencent is expected to enhance the company's market position [1] - The company was included in the newly launched Hong Kong Stock Exchange Technology 100 Index, which is anticipated to improve its liquidity [1] - Q3 operational data showed growth rates exceeding market expectations, suggesting that the company is likely to maintain high growth for the full year [1]

Group 1 - UiPath will join the S&P MidCap 400 Index, replacing Synovus Financial, with the change effective prior to trading on Friday [1][5] - The inclusion in the index is viewed as a bullish signal, potentially attracting new investors and funds that track the index [2][4] - UiPath shares increased approximately 5% in recent trading and have gained about 30% in value this year [4] Group 2 - S&P Dow Jones Indices also announced that Versant Media Group will replace Brandywine Realty Trust in the S&P SmallCap 600 Index, effective January 6 [3][5] - Comcast will remain in the S&P 500 Index despite the changes to the SmallCap 600 [3]

Group 1 - U.S. stock futures were mostly flat, with Nasdaq 100 futures slipping around 0.01% [1] - Sidus Space, Inc. announced a public offering of 19,230,800 shares at $1.30 per share, leading to a 39.2% decline in its shares to $1.39 in pre-market trading [1] Group 2 - Starfighters Space Inc shares dipped 23.2% to $24.19 after a significant gain of over 370% on Monday [2] - ECD Automotive Design, Inc. fell 15.4% to $0.1650 following a 1-for-5 reverse stock split announcement [2] - CapsoVision Inc dipped 5.6% to $12.35, while Rocket Lab Corp fell 5.3% to $73.46 after a previous 10% jump [2] - Intuitive Machines Inc declined 5.2% to $15.82 despite a price target increase from $14 to $20 by B. Riley Securities [2] - Firefly Aerospace Inc shares declined 4.4% to $27.33 after a 16% increase due to joining the Russell 2000 and Russell 3000 indexes [2] - AST SpaceMobile Inc shares declined 3.1% to $83.82 after a 14% surge related to new satellite details [2]

Core Viewpoint - UBS reports that Innovent Biologics (01801) has six new products and a new indication for sintilimab included in the latest National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] - Innovent Biologics has been officially included in the Hang Seng Index as of today [1] - UBS maintains a "Buy" rating with a target price of HKD 137.4 [1] Group 1 - The new products targeting IGF-1R, EGFR, BTK, ROS1, KRAS G12C, and RET are expected to see rapid sales growth by 2026 [1] - The inclusion of teriparatide for diabetes in the insurance list positively impacts the expected launch of masitinib in 2026, although price adjustments need to be monitored [1] - Inclusion in the Hang Seng Index is anticipated to further enhance liquidity for the company's stock [1]